Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20691312 | 0.92 | TYMP (0.39) | P2RY12P2RY2P2RY1P2RY6ADORA1 | |
| SCHEMBL20691938 | 0.86 | HIF1A (0.33) | P2RY1POLB | |
| SCHEMBL20691946 | 0.85 | P2RY12 (0.34) | P2RY12P2RY2P2RY1P2RY6ADORA1 | |
| SCHEMBL22349203 | 0.85 | STING1 (0.38) | POLB | |
| SCHEMBL17860588 | 0.81 | ADORA1 (0.40) | P2RY12P2RY2P2RY1P2RY6ADORA1 | |
| SCHEMBL11055621 | 0.80 | P2RY12 (0.40) | P2RY12ADORA1POLB | |
| SCHEMBL4727404 | 0.80 | ADORA1 (0.46) | ADORA1POLB | |
| SCHEMBL4727394 | 0.80 | ADORA1 (0.46) | ADORA1POLB | |
| SCHEMBL22858497 | 0.79 | P2RY12 (0.35) | P2RY12P2RY1ADORA1POLB | |
| SCHEMBL22858508 | 0.77 | P2RY12 (0.34) | P2RY12P2RY1ADORA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | P2RY12 1690/4885P2RY2 1259/4885P2RY1 1124/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | P2RY12 1690/4885P2RY2 1259/4885P2RY1 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.